Gilead Sciences (GILD) closed its last trading day at $62.32, up 1.02% from the previous trading session. The stock lagged behind the S&P 500's 2.59% gain on the day. Meanwhile, the Dow Jones is up 2.66% and the Tech-Nasdaq is up 0.07%.
YTD, shares of the HIV and Hepatitis C drug maker fell 3.34% over the past month, outpacing the medical sector's 3.87% loss and the S&P 500's 9.22% loss. during the period.
Investors will watch Gilead Sciences for strength as its next earnings report approaches. The company is expected to report earnings per share of $1.53, down 42.26% from the same quarter a year earlier. Meanwhile, the Zacks Consensus Revenue Forecast calls for net sales of $6.09 billion, down 17.95% year over year.
Our Zacks consensus estimate for full-year earnings per share is $6.63 and revenue is $25.27 billion, a year-over-year change of -8.93% and -7.46%, respectively. .
Investors should also pay attention to recent changes in Gilead Sciences analyst forecasts. This recent revision probably reflects the evolution of short-term business trends. Therefore, a positive rating change reflects analysts' optimism about the company's business and profitability.
Based on our research, we believe this valuation downgrade is directly related to closed team stock movements. We developed the Zack ranking to take advantage of this phenomenon. Our system takes these classification changes into account and provides a clear and actionable classification model.
Ranked #1 (Strong Buy) to #5 (Strong Sell), the Zacks ranking system has a proven, third-party audited track record, with the #1 stock averaging +25% return per year since 1988. Sachs consensus. EPS valuations increased 0.01% over the last month. Gilead Sciences currently ranks at Zacks Rank #3 (Hold).
Investors should also note Gilead Sciences' current sentiment, including its forward P/E of 9.31. This is a discount from the industry average forward P/E of 19.26.
We can also see that GILD currently has a PEG ratio of 0.59. This indicator is used similarly to the well-known P/E ratio, but the PEG ratio also takes into account the expected growth rate of stock earnings. At yesterday's close, the GILD branch had an average PEG ratio of 1.29.
The biomedical and genetic industries are part of the medical sector. The group is ranked 85th in the Zacks Industry Rankings, which means it is in the top 34% of more than 250 industries.
The Zacks Industry Rankings are ranked from best to worst in relation to the average Zacks rating of each company in each of those industries. Our research shows that the top 50% of stores outperform the bottom half by 2 to 1.
Be sure to keep an eye out for all of these and many other stock movement indicators at Zacks.com.
Click here to read this article on Zacks.com.